Clinical Features, Neurologic Recovery, and Risk Factors of Postoperative Posterior Fossa Syndrome and Delayed Recovery: a Prospective Study
Overview
Authors
Affiliations
Background: Posterior fossa syndrome (PFS) is a known consequence of medulloblastoma resection. Our aim was to clinically define PFS, its evolution over time, and ascertain risk factors for its development and poor recovery.
Methods: Children with medulloblastoma treated at St Jude Children's Research Hospital from 6/2013 to 7/2019 received standardized neurological examinations, before and periodically after radiation therapy. Most (98.3%) were enrolled on the ongoing multi-institutional protocol (SJMB12; NCT01878617).
Results: Sixty (34%) of 178 evaluated children had PFS. Forty (23%) had complete mutism (PFS1) and 20 (11%) had diminished speech (PFS2). All children with PFS had severe ataxia and 42.5% of PFS1 had movement disorders. By multivariable analysis, younger age (P = .0005) and surgery in a low-volume surgery center (P = .0146) increased PFS risk, while Sonic Hedgehog tumors had reduced risk (P = .0025). Speech and gait returned in PFS1/PFS2 children at a median of 2.3/0.7 and 2.1/1.5 months, respectively, however, 12 (44.4%) of 27 PFS1 children with 12 months of follow-up were nonambulatory at 1 year. Movement disorder (P = .037) and high ataxia score (P < .0001) were associated with delayed speech recovery. Older age (P = .0147) and high ataxia score (P < .0001) were associated with delayed gait return. Symptoms improved in all children but no child with PFS had normal neurologic examination at a median of 23 months after surgery.
Conclusions: Categorizing PFS into types 1 and 2 has prognostic relevance. Almost half of the children with PFS1 with 12-month follow-up were nonambulatory. Surgical experience was a major modifiable contributor to the development of PFS.
Giglio M, Corriero A, Perillo T, Varrassi G, Puntillo F Children (Basel). 2025; 11(12.
PMID: 39767839 PMC: 11674600. DOI: 10.3390/children11121410.
Yang W, Ren S, Li Y, Cai Y, Peng X, Sun H Eur Radiol. 2024; .
PMID: 39658685 DOI: 10.1007/s00330-024-11264-8.
Radu O, Balaci G, Leucuta D, Florian I Med Pharm Rep. 2024; 97(4):540-548.
PMID: 39502763 PMC: 11534376. DOI: 10.15386/mpr-2788.
Lim-Fat M, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J Neuro Oncol. 2024; 27(1):13-32.
PMID: 39441704 PMC: 11726256. DOI: 10.1093/neuonc/noae186.
Raches D, Gajjar A, Robinson G, Ashford J, Bryndziar M, Huggins A Cancers (Basel). 2024; 16(17).
PMID: 39272857 PMC: 11393926. DOI: 10.3390/cancers16172999.